Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay

@article{Mehta2001BreastCS,
  title={Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay},
  author={Rita S. Mehta and Richard A Bornstein and I Yu and Ricardo J. Parker and Christine E. McLaren and Khanh Luan P. Nguyen and K Li and John P Fruehauf},
  journal={Breast Cancer Research and Treatment},
  year={2001},
  volume={66},
  pages={225-237}
}
Purpose. To determine whether in vitro extreme drug resistance (EDR) assay results for patients with breast carcinoma were associated with clinical outcome after chemotherapy. Patients and methods. EDR assays were performed on tumor tissue obtained from 103 newly diagnosed breast cancer cases. EDR scores of 2 for low, 1 for intermediate, or 0 for extreme drug resistance were determined for each agent tested. In vitro EDR scores for 4-hydroxycyclophosphamide (4HC) and doxorubicin were summed for… CONTINUE READING
29 Citations
38 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 38 references

AG: In vitro determination of drug response: A discussion of clinical applications

  • JP Fruehauf, Bosanquet
  • Principles and Practice of Oncology Updates,
  • 1993
Highly Influential
4 Excerpts

HighDose Chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer: Results of the French Protocol Pegase 04

  • J-P Lotz, H Curé, +7 authors H Roché
  • Proc Am Soc Clin Oncol 18:
  • 1999

Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the Humanized Anti-HER2 Monoclonal Antibody Herceptin (H) in HER2-Overexpressing (HER2 +) metastatic breast cancer (MBC)

  • L Norton, D Slamon, +8 authors S Shak
  • Proc Am Soc Clin Oncol
  • 1999

Randomized, controlled trial of high dose chemotherapy (HD-CNVp) vs. standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer

  • WR Bezwoda
  • Proc Am Soc Clin Oncol 18:
  • 1999

Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy

  • Lotz J-P, H Curé, +7 authors H Roché
  • Proc Am Soc Clin Oncol
  • 1999

Similar Papers

Loading similar papers…